Business
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirmed receipt of the milestone payment.
About this update from Prism Biolab Co. Ltd
[{"type":"text","content":"TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirmed receipt of the milestone payment.","length":355,"tagName":"p"},{"type":"image","alt":"PRISM BioLab logo (PRNewsfoto/PRISM BioLab Co., Ltd.)","displaySize":"","headline":null,"caption":"PRISM BioLab logo (PRNewsfoto/PRISM BioLab Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":99,"url":"https://media.zenfs.com/en/prnewswire.com/d67e964c5280408946c03686dc3c0d59"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xRzCw3pY3D9VEjtsSb.3IA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/d67e964c5280408946c03686dc3c0d59","width":400,"height":99}},"href":"https://mma.prnewswire.com/media/2693058/PRISM_BioLab_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"PRISM and Ono have entered into a "Joint Research and Licensing Agreement" on April 25, 2024, (hereinafter "the Agreement") for drug discovery in the oncology field. Under this Agreement, PRISM received an upfront payment and joint research fees, launched a joint research project (hereinafter "the Project") to discover clinical candidate compounds against targets proposed by Ono, utilizing PRISM's proprietary peptide-mimetic technology "PepMetics". PepMetics® is a technology based on small molecules targeting protein-protein interactions (PPIs).","length":595,"tagName":"p"},{"type":"text","content":"The Project has progressed as planned under the collaboration of both companies, and has achieved the milestone defined in the Agreement for the drug discovery research stage. PRISM will receive the milestone payment and joint research fees from Ono. The milestone payment will be recorded as business revenue in the first quarter of PRISM's fiscal year ending September 2026 (October 1, 2025 – September 30, 2026). The joint research funding will be allocated proportionally throughout the period of the next phase of the joint research. While the specific amounts of the milestone payment and joint research fu...